FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer

FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer

Top 10 OncoGrants of the Week: Funding Translation, Implementation, and Oncology Capacity

OncoGrants

Oncology This Week: OncoDaily Weekly Dec 8–14, 2025

OncoDaily Weekly

10 Oncology Experts Join OncoDaily Medical Journal's Editorial Team

OncoDaily Medical Journal

ASCO Announces Featured Voices of the Gastrointestinal Cancers Symposium 2026

ASCO

Alessandro Gronchi: Two Decades of Progress in Retroperitoneal Sarcoma Outcomes

Alessandro Gronchi

Bishal Gyawali: Why De-Escalation Trials Can Be Designed as Superiority Instead of Non-Inferiority

Bishal Gyawali, De-Escalation Trials

Candle Lighting Day: A Global Moment of Remembrance and Solidarity 2025

Candle Lighting Day: A Global Moment of Remembrance and Solidarity 2025

20/02/2024